Karyopharm Therapeutics Inc.
KPTIAs of the close on Sep 25, 2026
Price
$1.62
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
EPS (TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Karyopharm Therapeutics Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 15 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated May 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Birchview Capital, LP | 2026-03-31 | 83,952 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-09-30 | 27,985 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-06-30 | 27,985 | Not shown | SEC filing |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 4,879 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-03-31 | 27,985 | Not shown | SEC filing |
| Palo Alto Investors LP | 2025-03-31 | 324,032 | Not shown | SEC filing |
| OSAIC HOLDINGS, INC. | 2024-12-31 | 5,390 | Not shown | SEC filing |
| Shay Capital LLC | 2024-12-31 | 172,153 | Not shown | SEC filing |
| EXCHANGE TRADED CONCEPTS, LLC | 2024-12-31 | 218,791 | Not shown | SEC filing |
| West Branch Capital LLC | 2024-12-31 | 48 | Not shown | SEC filing |
| WOLVERINE TRADING, LLC | 2024-12-31 | 10,273 | Not shown | SEC filing |
| Snowden Capital Advisors LLC | 2024-12-31 | 11,000 | Not shown | SEC filing |
| ELCO Management Co., LLC | 2024-12-31 | 16,177 | Not shown | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2024-12-31 | 161,708 | Not shown | SEC filing |
| FMR LLC | 2024-12-31 | 412,456 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2024-12-31 | 664,145 | Not shown | SEC filing |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 2024-12-31 | 1,483,727 | Not shown | SEC filing |
| Focus Partners Wealth | 2024-12-31 | 45,818 | Not shown | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2024-12-31 | 1,313,893 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-12-31 | 419,832 | Not shown | SEC filing |
- Each value is checked against Karyopharm Therapeutics Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Birchview Capital, LP: 27,985 shares reported 2025-09-30; 83,952 shares reported 2026-03-31.
- Birchview Capital, LP: 27,985 shares reported 2025-06-30; 27,985 shares reported 2025-09-30.
- Birchview Capital, LP: 27,985 shares reported 2025-03-31; 27,985 shares reported 2025-06-30.
- Palo Alto Investors LP: 4,907,001 shares reported 2024-12-31; 324,032 shares reported 2025-03-31.
- Palo Alto Investors LP: 5,102,193 shares reported 2024-09-30; 4,907,001 shares reported 2024-12-31.
- Baird Financial Group, Inc.: 37,800 shares reported 2024-09-30; 44,800 shares reported 2024-12-31.
- HSBC HOLDINGS PLC: 40,301 shares reported 2024-09-30; 40,301 shares reported 2024-12-31.
- D. E. Shaw & Co., Inc.: 1,047,396 shares reported 2024-09-30; 229,685 shares reported 2024-12-31.
- ADAGE CAPITAL PARTNERS GP, L.L.C.: 4,319,842 shares reported 2024-09-30; 6,319,842 shares reported 2024-12-31.
- BRIDGEWAY CAPITAL MANAGEMENT, LLC: 239,500 shares reported 2024-09-30; 239,500 shares reported 2024-12-31.
- JANE STREET GROUP, LLC: 204,750 shares reported 2024-09-30; 748,306 shares reported 2024-12-31.
- MB, LEVIS & ASSOCIATES, LLC: 1,500 shares reported 2024-09-30; 1,500 shares reported 2024-12-31.
Showing the 12 most recent filer reports.
77 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Karyopharm Therapeutics Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-02 · Paulson Richard A.: Larger than 113 of the 123 other insider sales of Common Stock on file. SEC filing
- 2025-03-04 · Paulson Richard A.: Larger than 112 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-06-07 · PAKIANATHAN DEEPIKA: Larger than 119 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-06-06 · PAKIANATHAN DEEPIKA: Larger than 116 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-06-05 · PAKIANATHAN DEEPIKA: Larger than all 123 other insider sales of Common Stock on file. SEC filing
- 2024-06-04 · PAKIANATHAN DEEPIKA: Larger than 121 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-06-03 · PAKIANATHAN DEEPIKA: Larger than 122 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-05-31 · PAKIANATHAN DEEPIKA: Larger than 117 of the 123 other insider sales of Common Stock on file. SEC filing
- 2024-02-29 · Paulson Richard A.: Larger than all 11 other insider sales of Common on file. SEC filing
- 2024-02-29 · Mason Michael: Larger than 10 of the 11 other insider sales of Common on file. SEC filing
- 2023-03-01 · Cheng Sohanya Roshan: Larger than 111 of the 123 other insider sales of Common Stock on file. SEC filing
- 2023-03-01 · Paulson Richard A.: Larger than 115 of the 123 other insider sales of Common Stock on file. SEC filing
- 2022-06-09 · PAKIANATHAN DEEPIKA: Larger than 118 of the 123 other insider sales of Common Stock on file. SEC filing
- 2022-06-08 · PAKIANATHAN DEEPIKA: Larger than 120 of the 123 other insider sales of Common Stock on file. SEC filing
- 2022-05-04 · Paulson Richard A.: Larger than 114 of the 123 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-14 | Rangwala Reshma · EVP & Chief Medical Officer | Common Stock | S — Open market or private sale | −408 | 9.50 | SEC filing |
| 2026-05-14 | Mano Michael · EVP, CLO&Secretary | Common Stock | S — Open market or private sale | −266 | 9.50 | SEC filing |
| 2026-05-14 | Paulson Richard A. · President and CEO | Common Stock | S — Open market or private sale | −2,203 | 9.50 | SEC filing |
| 2026-05-14 | Cheng Sohanya Roshan · EVP & Chief Commercial Officer | Common Stock | S — Open market or private sale | −324 | 9.50 | SEC filing |
| 2026-05-14 | Poulton Stuart · EVP, Chief Development Officer | Common Stock | S — Open market or private sale | −403 | 9.50 | SEC filing |
| 2026-05-14 | Abate Kristin · Chief Accounting Officer | Common Stock | S — Open market or private sale | −53 | 9.50 | SEC filing |
| 2026-04-21 | Rangwala Reshma · EVP & Chief Medical Officer | Common Stock | S — Open market or private sale | −449 | 8.94 | SEC filing |
| 2026-03-02 | Poulton Stuart · EVP, Chief Development Officer | Common Stock | S — Open market or private sale | −5,101 | 9.41 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-21 | Schor Chen · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-21 | Oliger Christy J. · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-21 | BOHLIN GAREN G · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-21 | Greene Barry E · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-21 | Su Zhen · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-21 | PAKIANATHAN DEEPIKA · Director | Common Stock | A — Grant, award, or other acquisition | +15,508 | SEC filing |
| 2026-05-13 | Mano Michael · EVP, CLO&Secretary | Common Stock | A — Grant, award, or other acquisition | +700 | SEC filing |
| 2026-05-13 | Abate Kristin · Chief Accounting Officer | Common Stock | A — Grant, award, or other acquisition | +121 | SEC filing |
Showing 8 of 12 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.